deltatrials
Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT02962076

Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia

Cardiac Positron Emission Tomography for Detection of Cardiac Sympathetic Dysinnervation to Guide Ablation of Ventricular Tachycardia

Sponsor: Biosense Webster, Inc.

Conditions Ventricular Tachycardia
Interventions [C-11] Meta-hydroxyephedrine radioactive tracer (MHED)
Updated 14 times since 2017 Last updated: Nov 13, 2024 Started: Sep 21, 2020 Primary completion: Mar 1, 2023 Completion: Oct 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Investigator departing institution and enrollment not met.

Other terminated trials from Biosense Webster, Inc.

More terminations from Biosense Webster, Inc.

Other Ventricular Tachycardia trials with similar outcome

Browse all Ventricular Tachycardia trials

Listed as NCT02962076, this EARLY_PHASE1 trial focuses on Ventricular Tachycardia and remains terminated or withdrawn. Sponsored by Biosense Webster, Inc., it has been updated 14 times since 2020, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~May 2020 · 22 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2023 · 17 months · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~May 2024 · 8 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated EARLY_PHASE1

  2. Jan 2025 — Sep 2025 [monthly]

    Terminated EARLY_PHASE1

    Status: Enrolling By Invitation → Terminated

  3. Sep 2024 — Jan 2025 [monthly]

    Enrolling By Invitation EARLY_PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Enrolling By Invitation EARLY_PHASE1

  5. May 2024 — Jul 2024 [monthly]

    Enrolling By Invitation EARLY_PHASE1

▶ Show 9 earlier versions

  1. Sep 2023 — May 2024 [monthly]

    Enrolling By Invitation EARLY_PHASE1

    Status: Suspended → Enrolling By Invitation

  2. May 2023 — Sep 2023 [monthly]

    Suspended EARLY_PHASE1

    Status: Recruiting → Suspended · Phase: NA → EARLY_PHASE1

  3. Feb 2023 — May 2023 [monthly]

    Recruiting NA

  4. Sep 2021 — Feb 2023 [monthly]

    Recruiting NA

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting

  6. May 2020 — Jan 2021 [monthly]

    Not Yet Recruiting NA

  7. Jul 2018 — May 2020 [monthly]

    Not Yet Recruiting NA

  8. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting NA

  9. Jan 2017 — Jun 2018 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biosense Webster, Inc.
  • Khaled Awad, MD
  • Washington University School of Medicine
Data source: Mercy Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations